Vocational School of Technical Sciences, Mus Alparslan University, Mus 49250, Turkey.
Department of Chemistry, Faculty of Arts and Sciences, Mus Alparslan University, Mus 49250, Turkey.
Anticancer Agents Med Chem. 2020;20(11):1368-1378. doi: 10.2174/1871520620666200410080648.
Isoindole-1,3(2H)-dione derivatives are known to have cytotoxic effects on many cancer cells. The anticancer activity of these compounds varies depending on the substituents attached to them. Therefore, the effect of substituents is very important when determining the anticancer activities of molecules. We have recently reported an example of the substituent effect. According to that work, the anticancer activity against HeLa, C6, and A549 cancer cell lines of isoindole- 1,3(2H)-dione compounds containing tert-butyldiphenylsilyl ether, azido, and hydroxyl groups was examined by our group. It was found that an isoindole-1,3(2H)-dione compound containing both tert-butyldiphenylsilyl ether group and azido groups showed higher anticancer activity than 5-fluorouracil and another isoindole-1,3(2H)- dione compound containing both azido and hydroxyl groups. After we discovered that tert-butyldiphenylsilyl ether group in the skeletal structure of isoindole-1,3(2H)-dione exhibits anticancer activity against HeLa, C6, and A549 cancer cell lines, we wanted to examine the anticancer activities of different silyl ether groups, i.e., OTMS, -OTBDPS, and -OTBDMS groups, and also -OH and -Br groups, by comparing them with each other according to the structure-activity relationship.
All of the synthesized compounds were characterized by 1H and 13C NMR spectra, IR spectroscopy, and mass spectra measurements. The IC50 values of these compounds were calculated for all cancer cell lines and compared with each other and cisplatin, which is a platinum-containing chemotherapeutic drug. Molecular modelling studies were carried out using the MOE software package.
It was found that compounds 13 and 16, containing both silyl ether (-OTBDMS) and -Br groups, showed higher anticancer activity than cisplatin against both Caco-2 and MCF-7 cell lines. Compounds 20 and 23 showed anticancer activity in MCF-7 cells and compounds 8, 9, 20, and 23 in Caco-2 cells. While compounds 20 and 23 have only a silyl ether (-OTMS) group, compounds 8 and 9 have only a -OH group. Molecular modelling studies indicated that compounds 8 and 13, as well as their analogs, may bind to the active site of hRS6KB1 (pdb: 4l3j), compound 11 may bind to the active site of human mTOR (pdb: 4jt5) and additionally, compounds 10-17 are expected to be both mutagenic and reactive according to the mutagenicity and reactivity calculations.
According to these results, the anticancer activities of isoindole-1,3(2H)-dione compounds (8 - 23) vary depending on the groups they contain and these groups affect each other's activities. Silyl ethers (-OTBDMS and -OTMS) and -OH and -Br groups in the skeletal structure of isoindole-1,3(2H)-dione can be regarded as anticancer agents. In this sense, compounds 13 and 16, containing both silyl ether (-OTBDMS) and - Br groups, may be regarded as alternative chemotherapeutic drugs. This work may lead to the synthesis of new isoindole-1,3(2H)-dione compounds containing different silyl ether groups and studies evaluating their anticancer activities or other biological properties.
已知异吲哚-1,3(2H)-二酮衍生物对许多癌细胞具有细胞毒性作用。这些化合物的抗癌活性因连接在其上的取代基而异。因此,在确定分子的抗癌活性时,取代基的影响非常重要。我们最近报告了一个取代基效应的例子。根据这项工作,我们小组研究了含有叔丁基二苯基硅醚、叠氮基和羟基的异吲哚-1,3(2H)-二酮化合物对 HeLa、C6 和 A549 癌细胞系的抗癌活性。结果发现,含有叔丁基二苯基硅醚基团和叠氮基团的异吲哚-1,3(2H)-二酮化合物的抗癌活性高于 5-氟尿嘧啶和另一种含有叠氮基和羟基的异吲哚-1,3(2H)-二酮化合物。在发现异吲哚-1,3(2H)-二酮骨架中的叔丁基二苯基硅醚基团对 HeLa、C6 和 A549 癌细胞系具有抗癌活性后,我们希望通过比较彼此来研究不同的硅醚基团,即 OTMS、-OTBDPS 和 -OTBDMS 基团,以及 -OH 和 -Br 基团的抗癌活性,根据构效关系。
所有合成的化合物均通过 1H 和 13C NMR 光谱、红外光谱和质谱测量进行了表征。计算了这些化合物在所有癌细胞系中的 IC50 值,并相互比较,同时与顺铂(一种含铂的化疗药物)进行了比较。使用 MOE 软件包进行了分子建模研究。
结果发现,含有硅醚(-OTBDMS)和 -Br 基团的化合物 13 和 16 对 Caco-2 和 MCF-7 细胞系的抗癌活性均高于顺铂。化合物 20 和 23 在 MCF-7 细胞中具有抗癌活性,化合物 8、9、20 和 23 在 Caco-2 细胞中具有抗癌活性。虽然化合物 20 和 23 仅含有硅醚(-OTMS)基团,但化合物 8 和 9 仅含有 -OH 基团。分子建模研究表明,化合物 8 和 13 及其类似物可能与 hRS6KB1 的活性位点(pdb:4l3j)结合,化合物 11 可能与人类 mTOR 的活性位点(pdb:4jt5)结合,此外,根据致突变性和反应性计算,化合物 10-17 预计既有致突变性又有反应性。
根据这些结果,异吲哚-1,3(2H)-二酮化合物(8-23)的抗癌活性取决于它们所包含的基团,这些基团相互影响。异吲哚-1,3(2H)-二酮骨架中的硅醚(-OTBDMS 和 -OTMS)和 -OH 和 -Br 基团可视为抗癌剂。从这个意义上说,含有硅醚(-OTBDMS)和 -Br 基团的化合物 13 和 16 可以被视为替代化疗药物。这项工作可能会导致合成含有不同硅醚基团的新型异吲哚-1,3(2H)-二酮化合物,并研究评估它们的抗癌活性或其他生物学特性。